03:16 PM EDT, 08/30/2024 (MT Newswires) -- Novavax ( NVAX ) got the US Food and Drug Administration's emergency use authorization for the updated COVID-19 vaccine designed to target current variants, including the Omicron JN.1 strain, the agency said Friday.

The vaccine is authorized for individuals aged 12 and older, aiming to enhance protection against serious outcomes, including hospitalization and death, the FDA said.

Novavax ( NVAX ) shares gained 5.5% in recent Friday trading.

Price: 12.03, Change: +0.63, Percent Change: +5.52